Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
Recent clinical studies showed that triple-negative breast cancer patients (ER-/PR-/HER2-)
may benefit more from Capecitabine chemotherapy. However, the optimum post-operative adjuvant
Capecitabine chemotherapy regimen has not been determined for Chinese population with
triple-negative breast cancer. Thus it's necessary to conduct a multi-center Phase III
clinical trial to verify efficacy and safety of Capecitabine in the treatment of
triple-negative breast cancer. In this study, a prospective, randomized, open, multi-center
Phase III clinical study was conducted to compare efficacy and safety of sequential Docetaxel
followed by Fluorouracil/Epirubicin/Cyclophosphamide (FEC) and sequential Docetaxel and
Capecitabine followed by Capecitabine/Epirubicin/Cyclophosphamide (XEC) as post-operative
adjuvant chemotherapy in the treatment of triple-negative breast cancer in Chinese
population.